

**INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY**  
 (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference POPI-II	<b>FOR FURTHER ACTION</b>	
	See Form PCT/PEA/416	
International application No. PCT/FI2004/000001	International filing date (day/month/year) 02.01.2004	Priority date (day/month/year) 03.01.2003
International Patent Classification (IPC) or national classification and IPC C07D207/16, C07D295/18, A61K31/401, A61K31/4025, A61K31/40		
Applicant ORION CORPORATION et al		

<p>1. This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 10 sheets, including this cover sheet.</p> <p>3. This report is also accompanied by ANNEXES, comprising:</p> <p>a. <input checked="" type="checkbox"/> (<i>sent to the applicant and to the International Bureau</i>) a total of 41 sheets, as follows:</p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).</li> <li><input type="checkbox"/> sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.</li> </ul> <p>b. <input type="checkbox"/> (<i>sent to the International Bureau only</i>) a total of (indicate type and number of electronic carrier(s)) , containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).</p>
<p>4. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Box No. I Basis of the opinion</li> <li><input type="checkbox"/> Box No. II Priority</li> <li><input checked="" type="checkbox"/> Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li><input checked="" type="checkbox"/> Box No. IV Lack of unity of invention</li> <li><input checked="" type="checkbox"/> Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li><input checked="" type="checkbox"/> Box No. VI Certain documents cited</li> <li><input type="checkbox"/> Box No. VII Certain defects in the international application</li> <li><input type="checkbox"/> Box No. VIII Certain observations on the international application</li> </ul>

Date of submission of the demand  30.07.2004	Date of completion of this report  21.03.2005
Name and mailing address of the International preliminary examining authority:   European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016	Authorized Officer  Seitner, I Telephone No. +31 70 340-2389



**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/FI2004/000001

**Box No. I Basis of the report**

1. With regard to the **language**, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.
  - This report is based on translations from the original language into the following language , which is the language of a translation furnished for the purposes of:
    - international search (under Rules 12.3 and 23.1(b))
    - publication of the international application (under Rule 12.4)
    - international preliminary examination (under Rules 55.2 and/or 55.3)
2. With regard to the **elements\*** of the international application, this report is based on (*replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report*):

**Description, Pages**

1, 2	as originally filed
3-35	received on 14.01.2005 with letter of 13.01.2005

**Claims, Numbers**

1(part)	as originally filed
1 (part), 2-15	received on 14.01.2005 with letter of 13.01.2005

- a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
- 3.  The amendments have resulted in the cancellation of:
  - the description, pages
  - the claims, Nos.
  - the drawings, sheets/figs
  - the sequence listing (*specify*):
  - any table(s) related to sequence listing (*specify*):
- 4.  This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
  - the description, pages
  - the claims, Nos.
  - the drawings, sheets/figs
  - the sequence listing (*specify*):
  - any table(s) related to sequence listing (*specify*):

\* If item 4 applies, some or all of these sheets may be marked "superseded."

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/FI2004/000001

**Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- the entire international application,  
 claims Nos. 13-15

because:

- the said international application, or the said claims Nos. 13-15 (with respect to industrial applicability) relate to the following subject matter which does not require an international preliminary examination (specify):

**see separate sheet**

- the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):  
 the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.  
 no international search report has been established for the said claims Nos.  
 the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:

the written form                     has not been furnished

does not comply with the standard

the computer readable form       has not been furnished

does not comply with the standard

- the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.

- See separate sheet for further details

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/FI2004/000001

**Box No. IV Lack of unity of invention**

1.  In response to the invitation to restrict or pay additional fees, the applicant has:
  - restricted the claims.
  - paid additional fees.
  - paid additional fees under protest.
  - neither restricted nor paid additional fees.
2.  This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
  - complied with.
  - not complied with for the following reasons:  
**see separate sheet**
4. Consequently, this report has been established in respect of the following parts of the international application:
  - all parts.
  - the parts relating to claims Nos. .

**Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes:	Claims	1-15
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-15
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-12
	No:	Claims	

2. Citations and explanations (Rule 70.7):

**see separate sheet**

**INTERNATIONAL PRELIMINARY REPORT  
ON PATENTABILITY**

International application No.  
PCT/FI2004/000001

---

**Box No. VI Certain documents cited**

---

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.

PCT/FI2004/000001

**Re Item III**

**Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

Claims 13-15 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

**Re Item IV**

**Lack of unity of invention**

**IV.1.** According to Rule 13.1 PCT, "The International application shall relate to one invention only OR to a group of inventions so linked as to form a single general inventive concept".

This is further clarified in Rule 13.2 PCT, which details that "the requirement for unity of invention shall only be fulfilled when there is a technical relationship among those inventions involving one or more of the same corresponding special technical features that defines a contribution which each of the claimed inventions, considered as a whole makes over the prior art".

**IV.2.** For the purpose of unity, a single general inventive concept is required. This means that the broadest possible problem to be solved has to be drawn up (i.e. to cover all claimed possibilities). Thus by definition, the provisos may not be taken into account when determining the presence or lack of unity, since the special technical feature must define a contribution over these provisos as well.

It is considered that the problem to be solved by the present application is the provision of further prolyl oligopeptidase inhibitors for the treatment of neurodegenerative diseases. The solution is provided by compounds according to the formula (I) of claim 1. Thus, the single general concept can be identified as the provision of compounds according to the formula (I) of claim 1 as prolyl oligopeptidase inhibitors for the treatment of neurodegenerative diseases

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.  
**PCT/FI2004/000001**

**IV.3. The following documents were retrieved during the preliminary search:**

D1: EP-A-0 536 399 (ZERIA PHARM CO LTD) 14 April 1993 (1993-04-14)

D1 discloses (see compound 6 and pages 1-2) prolyl oligopeptidase inhibitors of the present formula of claim 1 in which R1=benzofurane, R2=H, and R3=-CH<sub>2</sub>OH.

D2: EP-A-0 201 741 (SUNTORY LTD) 20 November 1986 (1986-11-20)

D2 discloses (see page 5 compounds SUAM 1231 and page 1) prolyl oligopeptidase inhibitors of the present formula of claim 1 in which R1=-(CH<sub>2</sub>)<sub>3</sub>-Ph, R2=H, and R3=CHO.

D3: EP-A-0 232 849 (SUNTORY LTD) 19 August 1987 (1987-08-19)

D3 discloses (see table 2, compound 18 and claim 4-5 ) prolyl oligopeptidase inhibitors of the present formula of claim 1 in which R1=-(CH<sub>2</sub>)<sub>3</sub>-Ph and R2=R3=H.

The compounds of D1-D3 solve the problem, namely the provision of further prolyl oligopeptidase inhibitors for the treatment of neurodegenerative diseases in an identical manner to the present application. Thus, D1-D3 provide solutions to the problem identified in the above mentioned single general concept. Therefore, the single general concept which could link the different inventions of the present application cannot be considered as inventive and there is a lack of unity.

**IV.4. In the light of the above, the examiner has identified two different subjects:**

1.) Claims 1(in part); 2-4; 8-15(in part):

Compounds according to the general formula (I) of claim 1 in which X represents N, as well as their pharmaceutical use and compositions according to claims 8-15

2.) Claims 1(in part); 5-7; 8-15(in part):

Compounds according to the general formula (I) of claim 1 in which X represents C, as well as their pharmaceutical use and compositions according to claims 8-15

**IV.5. This Authority chose not to invite the Applicant to pay additional fees and consequently, all parts of the application are subject to the following report.**

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.  
**PCT/FI2004/000001**

**Re Item V**

**Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

The following documents are referred to in this communication:

D4 : US 4 483 991 A (FREED MEIER E) 20 November 1984 (1984-11-20)

D5 : DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE,  
COLUMBUS, OHIO, US; FONTANELLA, L. ET AL: "Synthesis of 2,5- and 2,3,5-  
substituted hexahydropyrrolo[1,2- c]imidazolones" XP002286664;  
retrieved from STN; Database accession no. 1973:478688

D6 : EP 0 915 088 A (HOFFMANN LA ROCHE) 12 May 1999 (1999-05-12)

D7: WO 91/18891 A (PFIZER) 12 December 1991 (1991-12-12)

**V.1. Novelty:**

The compounds according to the present formula (I) of claim 1 have not been found disclosed in the prior and therefore the subject matter of **claims 1-15** is considered **novel** (Article 33(2) PCT).

**V.2. Inventive Step:**

**V.2.1. Subject matter regarding the first invention (X=N):**

Documents D1-D3 which are considered as closest prior art, disclose compounds (see point IV.3. above) which differ from the compounds of the present application, in that the first pyrrolidine ring is not substituted, whereas in the present formula (I) R2 may not be hydrogen (see proviso). From the teaching of the prior art, the skilled person had no incentive to exactly modify the 2-position of the first pyrrolidine ring by adding a substituent R2.

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.  
**PCT/FI2004/000001**

**V.2.2. Subject matter regarding the second invention (X=C):**

Document D7 which is considered to represent the most relevant state of the art for the compounds of present formula (I) in which X represents a carbon, disclose prolyl oligopeptidase inhibitors (see claims 1, 7-11 and examples 39-41), which differ from said compounds in that the double bond of the cyclopentene ring is located at a different position.

The problem to be solved may therefore be regarded as the provision of further prolyl oligopeptidase inhibitors for the treatment of neurodegenerative diseases.

D7 further discloses compounds in which the 5-membered carbocyclic ring is saturated. In view of this teaching the skilled person would assume that the saturation and/or the position of unsaturation does not represent a feature essential for the invention, i.e. for the prolyl oligopeptidase inhibitory activity of the compounds.

Therefore, the skilled person would have assumed that the alteration of the position of the double bond in the carbocyclic ring would have no effect on the biological activity.

It has however been demonstrated that the alteration of the position of the double bond in the carbocyclic ring has a significant effect on the prolyl oligopeptidase inhibitory activity of the compounds. That is, when determining the POP activity of pig brain, example 3 of the present application has shown an IC<sub>50</sub> value of 9 nM, whereas the corresponding compound having the double bond as in D7 has an IC<sub>50</sub> value of 230nM. This result is recognized as an unexpected effect associated with the novel structural features over the prior art.

**V.2.3. Consequently, the subject-matter of present claims 1-15 is considered as involving an inventive step (Article 33(3) PCT).**

**V.3. Industrial Applicability:**

The present application relates to compounds which are useful for the treatment of neurodegenerative diseases and the **subject matter of claims 1-12 is therefore considered as industrially applicable (Article 33(4) PCT)**.

For the assessment of the present claims 13-15 on the question whether they are

**INTERNATIONAL PRELIMINARY  
REPORT ON PATENTABILITY  
(SEPARATE SHEET)**

International application No.

**PCT/FI2004/000001**

industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

a straight or branched, unsubstituted or substituted alkenyl chain having 2 to 10 carbon atoms,

or a straight or branched, unsubstituted or substituted alkynyl chain having 2 to 10 carbon atoms;

5

$R_3$  is:

H, cyano, hydroxy, oxo, halogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein the said alkyl subgroups are unsubstituted or substituted,

10 or  $R_3$  is  $COOR^4$ ,  $COR^4$ ,  $CR^4(OR^5)_2$  or  $COCH_2OR^6$ , wherein  $R^4$  is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl are unsubstituted or substituted,  $R^5$  is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and  $R^6$  is lower acyl or halogen;

15

provided, that

- a) when X is N, the dotted line represents a single bond and  $R_2$  is not H;
- b) when X is C, the dotted line represents a double bond and  $R_2$  is H;
- c) the compound is not 5-ethoxycarbonyl-N-benzyloxycarbonyl-2-[(2'-(S)-benzylcarbonyl)-1'-pyrrolidinylcarbonyl]pyrrolidine or 1,2-pyrrolidinedicarboxylic acid, 5-(1-pyrrolidinylcarbonyl)-,1-(phenylmethyl) ester.

The present invention also relates to the pharmaceutically acceptable salts and esters of the compounds of the formula (I). Pharmaceutically acceptable salts, e.g. acid addition salts with both organic and inorganic acids are well known in the field of pharmaceuticals. Non-limiting examples of these salts include chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formates, tartrates, maleates, citrates, benzoates, salicylates and ascorbates. Pharmaceutically acceptable esters, when applicable, may be prepared by known methods using pharmaceutically acceptable acids that are conventional in the field of pharmaceuticals and that retain the pharmacological properties of the free form. Non-limiting examples of these esters include esters of aliphatic or aromatic alcohols, e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, *sec*-butyl and *tert*-butyl esters.

A further object of the invention is a pharmaceutical composition containing at least one pharmaceutically acceptable diluent, carrier, and/or excipient, as well as a therapeutically effective amount of a compound of the formula (I) as the active agent. Still a further

5 object of the invention is the use of the compounds of the formula (I) as a prolyl oligopeptidase inhibitor, for example in the treatment of neurodegenerative diseases, such as for Alzheimer's disease, and senile dementia, as well as for improving learning and memory functions. Furthermore, a method for the treatment of a disease or the enhancement of a condition where prolyl oligopeptidase inhibitors are indicated to be  
10 useful, e.g. a method for the treatment of neurodegenerative diseases, and/or for the improvement of learning and memory functions, is provided. In such a method a therapeutically effective amount of a compound of the invention is administered to a subject in need of such treatment. The use of the compounds of the invention for the manufacture of a medicament to be used for the above indication is also provided.

15 The compounds of formula (I), as well as the pharmaceutically acceptable salts and esters thereof, are referred to below as the compounds of the invention, unless otherwise indicated.

20 The invention includes within its scope all the possible stereoisomers of the compounds of formula (I), including geometric isomers, e.g. Z and E isomers (*cis* and *trans* isomers), and optical isomers, e.g. diastereomers and enantiomers. Furthermore, the invention includes in its scope both the individual isomers and any mixtures thereof, e.g. racemic mixtures. The individual isomers may be obtained using the corresponding isomeric  
25 forms of the starting material or they may be separated after the preparation of the end compound according to conventional separation methods. For the separation of optical isomers, e.g. enantiomers, from the mixture thereof the conventional resolution methods, e.g. fractional crystallisation, may be used.

30 **DETAILED DESCRIPTION OF THE INVENTION**

In the above-mentioned formula (I), the symbols have the following meanings:

X represents N or C.

The dotted line represents a single or a double bond.

- 5 A straight or branched alkyl chain in the meaning of R<sub>1</sub> has 1 to 10 carbon atoms. Such a group is unsubstituted or substituted with 1 to 3 substituent(s) each independently being COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub>, COCH<sub>2</sub>OR<sup>6</sup>, cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, nitro, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl,
- 10 cycloalkyl, cycloalkenyl, heterocycle, aryl or aralkyl, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is H, lower alkyl, lower acyl or halogen.

- 15 A straight or branched alkenyl chain in the meaning of R<sub>1</sub> has 2 to 10 carbon atoms. Such a group is unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group above.

- 20 A carbocyclic ring in the meaning of R<sub>1</sub>, or incorporated as a chain member in the alkyl or alkenyl group, is a saturated or unsaturated 3 to 7 membered ring with only carbon atoms in the ring. Such a group is unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above.

- 25 A heterocyclic ring in the meaning of R<sub>1</sub>, or incorporated as a chain member in the alkyl or alkenyl group, is a saturated or unsaturated 3 to 7 membered heterocyclic ring containing 1 to 3 heteroatom(s) selected from a nitrogen atom, an oxygen atom and/or sulphur atom. The heterocyclic group R<sub>1</sub> is unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above.

- 30 When R<sub>1</sub> is hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above.

A straight or branched alkyl chain in the meaning of R<sub>2</sub> has 1 to 10 carbon atoms. Such a group is unsubstituted or substituted with 1 to 3 substituent(s) each independently being hydroxy, oxo, lower alkoxy, amino, lower alkyl amino, halogen, carboxyl or lower acyl.

- 5 A straight or branched alkenyl chain in the meaning of R<sub>2</sub> has 2 to 10 carbon atoms. Such a group is unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>2</sub>, above.

- 10 A straight or branched alkynyl chain in the meaning of R<sub>2</sub> has 2 to 10 carbon atoms. Such a group is unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>2</sub>, above.

- 15 When R<sub>3</sub> is H, cyano, hydroxy, oxo, halogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, the said alkyl subgroups are unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>1</sub>, above.

- 20 When R<sub>3</sub> is COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub> or COCH<sub>2</sub>OR<sup>6</sup>, R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is lower acyl or halogen.

- 25 In the above-mentioned formula (I), the symbols have the meanings as described with the provisos that
- a) when X is N, the dotted line represents a single bond and R<sub>2</sub> is not H;
  - b) when X is C, the dotted line represents a double bond and R<sub>2</sub> is H;
  - 30 c) the compound is not 5-ethoxycarbonyl-N-benzyloxycarbonyl-2-[(2'-(S)-benzylcarbonyl)-1'-pyrrolidinylcarbonyl]pyrrolidine or 1,2-pyrrolidinedicarboxylic acid, 5-(1-pyrrolidinylcarbonyl)-,1-(phenylmethyl) ester.

The compounds of the invention may be converted, if desired, into their pharmaceutically acceptable salt or ester form using methods well known in the art.

A possible subgroup of the compound of formula (I) is a compound wherein

- 5    X is N;
- 
- the dotted line represents a single bond;
- R<sub>1</sub> is:
- a straight or branched alkyl chain having 1 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) each independently being COOR<sup>4</sup>, COR<sup>4</sup>,
- 10   CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub>, COCH<sub>2</sub>OR<sup>6</sup>, cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, nitro, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl or aralkyl, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is H, lower alkyl, lower acyl or halogen,
- 15   a straight or branched alkenyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group above, a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,
- 20   a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above, a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as
- 25   defined above, hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;
- 30   R<sub>2</sub> is: a straight or branched alkyl chain having 1 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) each independently being hydroxy, oxo, lower alkoxy, amino, lower alkyl amino, halogen, carboxyl or lower acyl,

a straight or branched alkenyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>2</sub>, above,

or a straight or branched alkynyl chain having 2 to 10 carbon atoms unsubstituted or

- 5    substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>2</sub>, above;

R<sub>3</sub> is:

H, cyano, hydroxy, oxo, halogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or

- 10    heterocycle, wherein the said alkyl subgroups are unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>1</sub>, above, or R<sub>3</sub> is COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub> or COCH<sub>2</sub>OR<sup>6</sup>, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is lower acyl or halogen, or a pharmaceutically acceptable salt or ester thereof; for example

20

wherein R<sub>1</sub> is

a straight or branched alkyl chain having 1 to 5 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino,

- 25    cycloalkyl or heterocycle,

a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,

a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or

- 30    substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,

a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as

defined above,

hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently

- 5 being lower alkyl or as defined for the alkyl group above;

$R_2$  is

a straight or branched alkyl chain having 1 to 5 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, oxo, lower alkoxy, amino, lower alkyl amino, halogen, carboxyl or lower acyl;

- 10  $R_3$  is:

H, cyano or  $COR^4$ , wherein  $R^4$  is H, lower alkyl, cycloalkyl, cycloalkenyl, heterocycle or aryl, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, cycloalkyl or heterocycle; or

- 15

wherein

$R_1$  is

a straight alkyl chain having 1 to 3 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being aryl, aryloxy, aryl lower alkoxy, lower alkyl

- 20 amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,

a 3 to 7 membered, saturated or unsaturated, unsubstituted heterocyclic ring,

lower alkoxy, lower alkyl amino, aryl amino or aryl lower alkyl amino;

$R_2$  is a straight or branched unsubstituted alkyl chain having 1 to 4 carbon atoms;

$R_3$  is:

- 25 H, cyano or  $COR^4$ , wherein  $R^4$  is H or lower alkyl, wherein the said lower alkyl is unsubstituted or substituted with hydroxy.

Another possible subgroup of the compound of formula (I) is a compound wherein

X is C;

- 30 the dotted line represents a double bond;

$R_1$  is:

a straight or branched alkyl chain having 1 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) each independently being  $COOR^4$ ,  $COR^4$ ,

$\text{CR}^4(\text{OR}^5)_2$ ,  $\text{COCH}_2\text{OR}^6$ , cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, nitro, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein  $\text{R}^4$  is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl or aralkyl,  $\text{R}^5$  is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and  $\text{R}^6$  is H, lower alkyl, lower acyl or halogen, a straight or branched alkenyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group above, a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,

<sup>10</sup> a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,

<sup>15</sup> a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as defined above, hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;

<sup>20</sup>  $\text{R}_2$  is H;  
 $\text{R}_3$  is:  
 H, cyano, hydroxy, oxo, halogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein the said alkyl subgroups are unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of  $\text{R}_1$ , above, or  $\text{R}_3$  is  $\text{COOR}^4$ ,  $\text{COR}^4$ ,  $\text{CR}^4(\text{OR}^5)_2$  or  $\text{COCH}_2\text{OR}^6$ , wherein  $\text{R}^4$  is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,  $\text{R}^5$  is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and  $\text{R}^6$  is lower acyl or halogen, or a pharmaceutically

acceptable salt or ester thereof; for example

wherein

$R_1$  is

- 5 a straight or branched alkyl chain having 1 to 5 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,
- 10 a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,
- 15 a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,
- 20 a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as defined above,  
hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;
- 25  $R_3$  is:  
H, cyano or  $COR^4$ , wherein  $R^4$  is H, lower alkyl, cycloalkyl, cycloalkenyl, heterocycle or aryl, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, cycloalkyl or heterocycle; or

wherein

$R_1$  is

- 30 a straight or branched alkyl chain having 1 to 3 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being, aryl, aryloxy, aryl lower alkoxy, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, a 3 to 7 membered, saturated or unsaturated, unsubstituted heterocyclic ring,

lower alkoxy, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the amino subgroups are unsubstituted or substituted with lower alkyl; R<sub>3</sub> is:

- H, cyano or COR<sup>4</sup>, wherein R<sup>4</sup> is H or lower alkyl, wherein the said lower alkyl is  
5      unsubstituted or substituted with hydroxy.

The various substituents and groups used in this application are defined as follows.

"Lower alkyl" means a straight or branched saturated hydrogen carbon chain having 1 to  
10     7, possibly 1 to 5 carbon atom(s). Representative examples include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, *sec*-butyl, *tert*-butyl, pentyl, and the like.

"Lower alkenyl" means a straight or branched unsaturated hydrogen carbon chain having  
2 to 7, possibly 2 to 5 carbon atoms, and containing (a) double bond(s). Representative  
15     examples include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and the like.

"Lower alkynyl" means a straight or branched unsaturated hydrogen carbon chain having  
2 to 7, possibly 2 to 5 carbon atoms, and containing (a) triple bond(s). Representative  
20     examples include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and the like.

"Lower alkoxy" as such or in the group "aryl lower alkoxy", is an alkoxy group having 1 to 7, possibly 1 to 5 carbon atom(s). Representative examples include, but are not limited  
25     to, methoxy, ethoxy, propoxy, isopropoxy, buoxy, *sec*-butoxy, *tert*-butoxy and pentoxy, phenyl methoxy, phenyl ethoxy, and the like.

"Lower alkyl amino" is an alkyl or dialkyl amino having 1 to 7 carbon atom(s) in the alkyl group(s). Representative examples include, but are not limited to, methyl amino, ethyl amino, propyl amino, isopropyl amino, butyl amino, pentyl amino, dimethyl amino, diethyl amino, N-ethyl-N-methyl amino, and the like.

"Lower acyl" is an acyl group having 2 to 7 carbon atoms. Representative examples

include, but are not limited to, acetyl, propanoyl, isopropanoyl, butanoyl, *sec*-butanoyl, *tert*-butanoyl, pentanoyl, and the like.

A "cycloalkyl", a "cycloalkenyl group" or a "carbocyclic ring" is a saturated or

- 5 unsaturated cyclic hydrocarbon group containing 3 to 7, possibly 5 to 7 carbon atom(s). Representative examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, phenyl, and the like.

A "heterocyclic ring" or a "heterocycle" group is a saturated or unsaturated 3 to 7,

- 10 possibly 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatom(s) selected from a nitrogen atom, an oxygen atom and/or sulphur atom. Representative examples include, but are not limited to, pyrrole, pyridine, pyrimidine, azepine, furan, pyran, oxepine, thiophene, thiopyran, thiepine, thiazole, imidazole, tetrazole, or their corresponding hydrated or partially hydrated derivatives, and the like.

15

"Aryl" as such or as a part of an "aralkyl", especially an "aryl lower alkyl" group, or as a part of an "aryloxy" or "aryl amino" is an aromatic group with 6 to 12 carbon atoms, and is possibly a monocyclic aryl group, such as a phenyl group.

20

"Halogen atom" means chlorine, bromine, fluorine or iodine.

In general, the compounds of formula (I) can be synthesized starting from compounds 1a and 1b and compounds of the general structure 2 according to Schemes 1 and 2.

25

The compounds 1a and 1b are synthesized according to Nöteberg, D. *et al.* (*J. Med. Chem.* 2000, 43, 1705-1713).

Compounds of structure 2, with varying R2 groups and with or without varying

protecting groups PG, are synthesized according to known synthesis methods described


30

in the literature by for example Beausoleil, E. *et al.* (*J. Org. Chem.* 1996, 61, 9447-9454), Collado, I. *et al.* (*J. Org. Chem.* 1995, 60, 5011-5015), Gershon, H. *et al.* (*J. Org. Chem.* 1961, 26, 2347-2350), Ho, T. L. *et al.* (*J. Org. Chem.* 1986, 51, 2405-2408), Ibrahim, H.


H. et al. (*J. Org. Chem.* 1993, **58**, 6438-6441), Overberger, C. G. et al. (*Macromolecules* 1972, **5**, 368-372), Pyne, S. G. et al. (*Tetrahedron* 1995, **51**, 5157-5168), Sanno, Y. et al. (*Yakugaku Zasshi* 1958, **78**, 1113-1118), Van der Werf, A. et al. (*Tetrahedron Lett.* 1991, **32**, 3727-3730), Wei, L. et al. (*Org. Lett.* 2000, **2**, 2595-2598), and Wistrand, L.-G. et al. (Tetrahedron 1991, **47**, 573-582).

5

Scheme 1



Scheme 2



The reactions in Schemes 1 and 2 can be of the following types: a) formation of ketones from aldehydes and organometal reagents such as Grignard reagents, b) formation of amides from carboxylic acids and amines, and c) deprotection of protective groups such as esters and carbamates. All of these reaction are well known in the field of organic chemistry.

- 5      The reactions in Schemes 1 and 2 can be of the following types: a) formation of ketones from aldehydes and organometal reagents such as Grignard reagents, b) formation of amides from carboxylic acids and amines, and c) deprotection of protective groups such as esters and carbamates. All of these reaction are well known in the field of organic chemistry.
- 10     For the formation of a salt with the compounds of the formula (I) any suitable, pharmaceutically acceptable acid or base can be used, such as hydrochloric, hydrobromic, sulphuric, phosphoric or nitric acid, or an organic acid, such as acetic acid, propionic, succinic, glycolic, lactic, maleic, malonic, tartaric, citric, fumaric, methanesulfonic, p-toluene sulfonic and ascorbic acid, as well as salts with amino acids, such as aspartic and glutamic acid. Suitable inorganic bases are, for example, the alkali, earth alkaline metal 15     or ammonium hydroxides and carbonates, as well as organic bases, such as organic amines, for example trialkyl amines, pyridine etc.

- It has been found that the presence of the substituent R<sub>2</sub> in compounds, wherein X is N and the dotted line in the formula (I) represents a single bond, and the presence of the 20     double bond represented by the dotted line in the formula (I) in compounds, wherein X is

C, result in increased inhibitory activity.

The novel compounds according to the invention may be used to treat any condition, which responds to a treatment with a prolyl oligopeptidase inhibitor. The compound

- 5 according to the invention can be administered for example orally, parenterally, topically or rectally by means of any pharmaceutical formulation useful for said administration, and containing the said compound in pharmaceutically acceptable and effective amounts together with pharmaceutically acceptable carriers, adjuvants or vehicles known in the art. The manufacture of such pharmaceutical formulations is well known in the art.

10

Thus the pharmaceutical composition may be in a dosage form suitable for oral use, such as tablets, capsules, liquid dosage forms, e.g. as suspensions, emulsions, syrups etc. All such formulations are made using *per se* known formulation techniques and carriers, adjuvants and additives. The compounds according to the invention may also be

- 15 administered parenterally, e.g. for infusion and injection, for example using aqueous or oily suspensions, emulsions, or dispersions containing the active agent in combination with conventional pharmaceutically acceptable excipients. Formulations for rectal use are e.g. suppositories containing the active agent in combination with carrier substances suitable for rectal use.

20

The therapeutic dose to be given to a patient in need of treatment will vary depending on the body weight and age of the patient, the particular condition being treated, as well as the manner of administration, and are easily determined by a person skilled in the art.

- Typically a dosage form for oral use containing 0.01 mg to 5 g, typically 0.1mg to 500 mg of active agent to be administered 1 to 3 times daily, would be suitable for most purposes.

The following examples illustrate the invention without limiting the same in any way.

### 30 GENERAL SYNTHESIS PROCEDURES

Positive ion mass spectra were acquired with ESI-MS, using a Finnegan MAT LCQ quadropole ion trap mass spectrometer equipped with an ESI source. Decoupled  $^{13}\text{C}$

NMR spectra were recorded on a Bruker Avance 500 spectrometer (125.8 MHz for  $^{13}\text{C}$ ) or a Bruker AM 400 spectrometer (100.6 MHz for  $^{13}\text{C}$ ),  $\text{CDCl}_3$  was used as solvent and chemical shifts are expressed in ppm relative to tetramethylsilane as internal standard.

Combustion analysis for CHN were measured on an EA1110 ThermoQuest CE

5 Instruments elemental analysator. All chemicals and solvents were of commercial quality and were purified if necessary following standard procedures. Some intermediate products and all end products were purified by flash chromatography (30-60  $\mu\text{m}$  Silica gel for flash, J.T. Baker) with a suitable eluent.

10 **Procedure A: General procedure for synthesis of 2-(1-hydroxy-alkyl)-cyclopent-2-ene-carboxylic acids**

A solution of 2-formyl-cyclopent-2-ene-carboxylic acid (1.0 mmol) in anhydrous diethyl ether was added to the alkyl magnesium bromide (prepared from the corresponding alkyl bromide (2-4 mmol) and magnesium (2-4 mmol) in anhydrous diethyl ether using a

15 crystal of iodine as the initiator) at rt. After 2 h the reaction mixture was poured into cold saturated  $\text{NH}_4\text{Cl}$ . The solution was made acidic with hydrochloric acid and the product was extracted with dichloromethane. The dichloromethane layer was dried and evaporated.

20 **Procedure B: General procedure for synthesis of 2-acyl-cyclopent-2-ene-carboxylic acids**

Dimethyl sulfoxide (2-3 mmol) was added to a solution of oxalyl chloride (1.0-1.5 mmol) in dichloromethane (4 ml) at -80 °C. After 15 min a solution of 2-(1-hydroxy-alkyl)-cyclopent-2-ene-carboxylic acid (1.0 mmol) in dichloromethane (2 ml) was added. The

25 reaction mixture was allowed to react for 1 h at -80 °C, where after triethyl amine (4-6 mmol) was added. The reaction mixture was stirred further 5 min at -80 °C before it was allowed to warm to rt. The organic phase was extracted with 5 % NaOH. The aqueous phase was made acidic with hydrochloric acid and the product was extracted with dichloromethane. The dichloromethane phase was dried and evaporated.

30

**Procedure C: General procedure for coupling an amine to a carboxylic acid with pivaloyl chloride**

Pivaloyl chloride (1.0 mmol) was added to a solution of the carboxylic acid (1.0 mmol)

and triethyl amine (1.1 mmol) in dichloromethane at 0 °C. After 1 h triethyl amine (1.1 mmol, or if the amine is in the form of a HCl or trifluoroacetic acid salt then 3.3 mmol) and the amine (1.0-1.1 mmol) was added, where after the reaction mixture was allowed to react 3-20 h at rt. The dichloromethane solution was washed with 30 % citric acid, 5 saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was dried and evaporated.

**Procedure D: Procedure for hydrolyzing a methyl or ethyl ester group**

Lithium hydroxide (1.5-6.0 mmol) and carboxylic acid ester (1.0 mmol) were dissolved 10 in a small volume of water-methanol. After the reaction was complete the solvent methanol was evaporated and water was added. The aqueous phase was washed with dichloromethane. The aqueous phase was then made acidic with hydrochloric acid and the product was extracted with dichloromethane. The dichloromethane phase was dried and evaporated.

15

**Procedure E: Deprotecting a Boc protected amine**

The Boc protected amine (1.0 mmol) was dissolved in dichloromethane (5-10 ml) and trifluoroacetic acid (2-4 ml) was added at 0 °C. The reaction was stirred at 0 °C for 2 h. The solvent was evaporated, yielding the trifluoroacetic acid salt of the amine.

20

**Procedure F: Hydrolysis of an O-acetyl group**

K<sub>2</sub>CO<sub>3</sub> (1.1 mmol) was added to a solution of O-acetyl compound (1.0 mmol) in water-methanol (6 ml) at 0 °C. The reaction was stirred 10 min at 0 °C and then 50 min at rt. The solvent methanol was evaporated. Dichloromethane and saturated NaCl were added 25 and the phases were separated. The dichloromethane phase was washed once with saturated NaCl. The dichloromethane phase was dried and evaporated.

**Procedure G: Converting a carboxylic acid to a carboxylic acid amide**

Ethyl chloroformate (1.0 mmol) was added to a solution of the carboxylic acid (1.0 mmol) and triethyl amine (1.0 mmol) in anhydrous tetrahydrofuran at -10 °C. After 20 min 25 % NH<sub>3</sub> (0.068 ml) was added at -10 °C. The reaction mixture was stirred at rt overnight. The solvent was evaporated and the residue was dissolved in dichloromethane. The dichloromethane phase was washed with saturated NaHCO<sub>3</sub>. The dichloromethane

phase was then dried and evaporated.

**Procedure H: Converting a carboxylic acid amide to a cyano group**

Trifluoroacetic anhydride (1.5 mmol) was added to a solution of carboxylic acid amide

- 5 (1.0 mmol) and triethyl amine (3 mmol) in anhydrous tetrahydrofuran. After 2-3 h water (10 ml) was added and the solvent was evaporated. The residue was dissolved in dichloromethane. The dichloromethane solution was washed with 30 % citric acid, saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was then dried and evaporated.

10

**PREPARATION OF STARTING MATERIALS**

**L-Proline methyl ester HCl salt**

Thionyl chloride (16 ml, 220 mmol) was added to a solution of L-proline (10 g, 87

- 15 mmol) in methanol (200 ml) at 0 °C. The reaction mixture was refluxed for 1 h. The solvent was evaporated, yield 14 g (86 mmol).

**Boc-2(S)-(acetoxycetyl)pyrrolidine**

Ethyl chloroformate (3.14 ml, 33 mmol) was added to a solution of Boc-L-proline (6.46

- 20 g, 30 mmol) and triethyl amine (4.60 ml, 33 mmol) in anhydrous tetrahydrofuran (100 ml) at -20 °C. The reaction mixture was stirred at -20 °C for 30 min. Then a diethyl ether solution of diazomethane (prepared according to Aldrich Technical Bulletin AL-180 from N-methyl-N-nitroso-4-toluenesulfonamide (6.4 g, 30 mmol)) was added to the reaction mixture at -20 °C. The reaction mixture was stirred at -20 °C for 1 h, where after the 25 reaction mixture was left without stirring at -20 °C overnight. Toluene (120 ml) was added, and the organic phase was washed with saturated NaHCO<sub>3</sub> and water. The organic phase was dried and evaporated. The residue was dissolved acetic acid (30 ml) and the solution was stirred at 100 °C for 10 min. The reaction mixture was evaporated. The residue was dissolved in ethyl acetate and the solution was washed with saturated 30 NaHCO<sub>3</sub> and water. The ethyl acetate phase was dried and evaporated. The product was purified by flash chromatography, yield 1.94 g (7.2 mmol).

## SYNTHESIS OF THE PRODUCT COMPOUNDS

### EXAMPLE 1

**5      2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid methyl ester**

Dicyclohexylcarbodiimide (3.06 g, 14.8 mmol) was added to a solution of cyclopent-2-ene-1,2-dicarboxylic acid 1-methyl ester (1.68 g, 9.9 mmol), benzyl amine (1.62 ml, 14.8 mmol), hydroxybenzotriazole (2.27 g, 14.8 mmol) and triethyl amine (2.07 ml, 14.8 mmol) in acetonitrile at 0 °C. After 30 min the reaction was allowed to warm to rt and it 10 was left at rt overnight. The solvent was evaporated and the residue was dissolved in dichloromethane. The dichloromethane solution was washed with saturated NaHCO<sub>3</sub>, saturated NaCl and 30 % citric acid. The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 2.58 g (9.9 mmol).

**15     2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid**

The methyl ester group of 2-benzylcarbamoyl-cyclopent-2-ene-carboxylic acid methyl ester (2.58 g, 9.9 mmol) was hydrolyzed according to procedure D. Yield 2.19 g (8.9 mmol).

**20     2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid (L-proline methyl ester)  
amide**

2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid (2.19 g, 8.9 mmol) and proline methyl ester (1.48 g, 8.9 mmol) were coupled according to procedure C. Purification by flash chromatography, yield 2.64 g (7.4 mmol).

**25     2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid L-proline amide**

The methyl ester group of 2-(benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid (L-proline methyl ester) amide (2.64 g, 7.4 mmol) was hydrolyzed according to procedure D. Yield 2.32 g (6.8 mmol).

**30     2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid L-prolylamide amide**

Prepared according to procedure G using 2-(benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid (2.32 g, 6.8 mmol) as the starting material. Purification by flash

chromatography, yield 2.3 g (6.8 mmol).

**2-(Benzylcarbamoyl)-cyclopent-2-ene-carboxylic acid 2(S)-cyanopyrrolidine amide**

Prepared according to procedure H using 2-(benzylcarbamoyl)-cyclopent-2-ene-

- 5 carboxylic acid L-prolylamide amide (2.3 g, 6.8 mmol). Purification and separation of diastereomers by flash chromatography, yield of one of the diastereomers 0.12 g, (0.37 mmol).

$^{13}\text{C}$  NMR:  $\delta$  25.22, 27.88, 30.00, 33.04, 43.43, 46.47, 46.76, 48.99, 118.73, 127.41, 127.64, 128.69, 137.80, 138.27, 139.45, 165.06, 173.96.

- 10 Anal. ( $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_2 \cdot 0.3 \text{ H}_2\text{O}$ ) calcd C: 69.41, H: 6.62, N: 12.78; found C: 69.51, H: 6.54, N: 12.58.

**EXAMPLE 2**

- 15 **2-Benzylcarbamoyl-cyclopent-2-ene-carboxylic acid 2(S)-(acetoxyacetyl)-pyrrolidine amide**

2-Benzylcarbamoyl-cyclopent-2-ene-carboxylic acid (0.86 g, 3.5 mmol) and 2(S)-(acetoxyacetyl)pyrrolidine trifluoroacetic acid salt (prepared from Boc-2(S)-(acetoxyacetyl)pyrrolidine (0.95 g, 3.5 mmol) according to procedure E) were coupled 20 according to procedure C. Purification by flash chromatography, yield 0.82 g (2.1 mmol).

**2-Benzylcarbamoyl-cyclopent-2-ene-carboxylic acid 2(S)-(hydroxyacetyl)-pyrrolidine amide**

The acetyl group of 2-benzylcarbamoyl-cyclopent-2-ene-carboxylic acid 2(S)-(acetoxyacetyl)-pyrrolidine amide (0.82 g, 2.1 mmol) was hydrolyzed according to 25 procedure F. Purification and separation of diastereomers by flash chromatography, yield of the more active diastereomer 0.21 g (0.58 mmol).

$^{13}\text{C}$  NMR:  $\delta$  25.15, 27.55, 28.51, 32.94, 43.47, 47.80, 49.00, 61.20, 67.06, 127.40, 127.64, 128.66, 138.24, 138.36, 139.11, 165.80, 174.21, 209.28.

- 30 ESI-MS:  $m/z$  357 ( $\text{M}+\text{H}$ )<sup>+</sup>.

Anal. ( $\text{C}_{20}\text{H}_{24}\text{N}_2\text{O}_4 \cdot 0.1 \text{ H}_2\text{O}$ ) calcd C: 67.06, H: 6.81, N: 7.82; found C: 66.98, H: 6.86, N: 7.62.

**EXAMPLE 3****2-Benzylcarbamoyl-cyclopent-2-ene-carboxylic acid pyrrolidine amide**

2-Benzylcarbamoyl-cyclopent-2-ene-carboxylic acid (0.46 g, 1.9 mmol) and pyrrolidine

- 5 (0.16 ml, 1.9 mmol) were coupled according to procedure C. Purification by flash chromatography, yield of the racemic product 0.39 g (1.3 mmol).

$^{13}\text{C}$  NMR:  $\delta$  24.36, 26.13, 28.12, 32.75, 43.36, 45.93, 46.90, 49.50, 127.21, 127.64, 128.57, 137.55, 138.60, 140.05, 165.61, 173.22.

ESI-MS:  $m/z$  299 ( $\text{M}+\text{H}$ ) $^+$ .

- 10 Anal. ( $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_2 \cdot 0.2 \text{ H}_2\text{O}$ ) calcd C: 71.59, H: 7.48, N: 9.28; found C: 71.43, H: 7.55, N: 9.19.

**EXAMPLE 4**

- 15 **2-(1-Hydroxy-2-phenyl-ethyl)-cyclopent-2-ene-carboxylic acid**

Prepared according to procedure A using 2-formyl-cyclopent-2-ene-carboxylic acid (2.1 g, 15.0 mmol) and benzyl bromide (7.2 ml, 60 mmol) as the starting materials.

Purification by flash chromatography, yield 0.80 g (3.5 mmol).

- 20 **2-Benzylcarbonyl-cyclopent-2-ene-carboxylic acid**

2-(1-Hydroxy-2-phenyl-ethyl)-cyclopent-2-ene-carboxylic acid (0.26 g, 1.1 mmol) was oxidized according to procedure B. Purification by flash chromatography, yield 0.074 g (0.32 mmol).

- 25 **2-Benzylcarbonyl-cyclopent-2-ene-carboxylic acid pyrrolidine amide**

2-Benzoyl-cyclopent-2-ene-carboxylic acid (0.14 g, 0.61 mmol) and pyrrolidine (0.051 ml, 0.67 mmol) were coupled according to procedure C. Purification by flash chromatography, yield of the racemic product 0.12 g (0.42 mmol).

$^{13}\text{C}$ -NMR:  $\delta$  24.43, 26.11, 28.15, 33.79, 45.67, 45.84, 46.89, 47.92, 126.72, 128.52,

- 30 129.50, 134.88, 145.20, 146.72, 172.83, 195.46.

ESI-MS:  $m/z$  284 ( $\text{M}+\text{H}$ ) $^+$ .

Anal. ( $\text{C}_{18}\text{H}_{21}\text{NO}_2$ ) calcd C: 76.30, H: 7.47, N: 4.94; found: C: 76.17, H: 7.69, N: 4.94.

**EXAMPLE 5****2-(1-Hydroxy-4-phenyl-butyl)-cyclopent-2-ene-carboxylic acid**

Prepared according to procedure A using 2-formyl-cyclopent-2-ene-carboxylic acid (2.1

5 g, 15 mmol) and 1-brom-3-phenylpropane (4.8 g, 31.5 mmol) as the starting materials.

Purification by flash chromatography, yield 1.31 g (5.0 mmol).

**2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid**

2-(1-Hydroxy-4-phenyl-butyl)-cyclopent-2-ene-carboxylic acid (1.31 g, 5.0 mmol) was

10 oxidized according to procedure B. Purification by flash chromatography, yield 0.39 g  
(1.5 mmol).

**2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid (L-proline methyl ester)  
amide**

15 2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid (0.58 g, 2.3 mmol) and proline  
methyl ester (0.37 g, 2.3 mmol) were coupled according to procedure C. Yield 0.64 g (1.7  
mmol).

**2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid L-proline amide**

20 The methyl ester group of 2-(4-phenylbutanoyl)-cyclopent-2-ene-carboxylic acid (L-  
proline methyl ester) amide (0.64 g, 1.7 mmol) was hydrolyzed according to procedure D.  
Yield 0.58 g (1.6 mmol).

**2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid L-prolylamide amide**

25 Prepared according to procedure G using 2-(4-phenylbutanoyl)-cyclopent-2-ene-  
carboxylic acid L-proline amide (0.58 g, 1.6 mmol) as starting material. Purification by  
flash chromatography, yield 0.50 g (1.4 mmol).

**2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid 2(S)-cyanopyrrolidine amide**

30 Prepared according to procedure H using 2-(4-phenylbutanoyl)-cyclopent-2-ene-  
carboxylic acid L-prolylamide amide (0.50 g, 1.4 mmol). Purification and separation of  
diastereomers by flash chromatography, yield of the more active diastereomer 190 mg  
(0.56 mmol).

<sup>13</sup>C NMR: δ 24.74, 25.20, 27.41, 29.52, 33.16, 34.62, 37.33, 45.97, 46.29, 47.00, 118.31, 125.41, 127.84, 127.98, 141.10, 144.10, 145.86, 173.20, 197.84.

ESI-MS: *m/z* 337.0 (M+H)<sup>+</sup>.

Anal. (C<sub>21</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>· 0.1 H<sub>2</sub>O) calcd C: 74.57, H: 7.21, N: 8.28; found C: 74.28, H: 7.53,

5 N: 7.93.

## EXAMPLE 6

### 2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid pyrrolidine amide

- 10 2-(4-Phenylbutanoyl)-cyclopent-2-ene-carboxylic acid (0.23 g, 0.89 mmol) and pyrrolidine (0.074 ml, 0.89 mmol) were coupled according to procedure C. Purification by flash chromatography, yield of the racemic product 0.21 g (0.69 mmol).  
<sup>13</sup>C NMR: δ 24.45, 25.68, 26.15, 28.07, 33.56, 35.19, 37.99, 45.82, 46.89, 47.84, 125.84, 128.31, 128.53, 141.80, 145.27, 145.39, 172.92, 198.28.  
15 ESI-MS: *m/z* 312 (M+H)<sup>+</sup>.  
Anal. (C<sub>20</sub>H<sub>25</sub>NO<sub>2</sub>) calcd C: 77.14, H: 8.09, N: 4.50; found C: 77.09, H: 8.30, N: 4.38.

## EXAMPLE 7

- 20 **(2S)-5-Oxo-2-[N-(benzyloxycarbonyl)-amino]hexanoic acid methyl ester**  
(2S)-5-Oxo-2-[N-(benzyloxycarbonyl)-amino]hexanoic acid (3.45 g, 12.3 mmol) (prepared according to Ho, T. L. *et al.* (*J. Org. Chem.* 1986, 51, 2405-2408)) was methylated with a small excess of diazomethane (prepared according to Aldrich Technical Bulletin AL-180) in anhydrous tetrahydrofuran at 0 °C. The reaction mixture was left at 4 °C overnight. The solvent was evaporated and the residue was dissolved in diethyl ether. The diethyl ether phase was washed with water and saturated NaHCO<sub>3</sub>. The diethylether phase was dried and evaporated. Purification by flash chromatography, yield 1.5 g (5.1 mmol).
- 25 **Boc-5(R)-methyl-L-proline methyl ester**  
Prepared by reacting (2S)-5-oxo-2-[N-(benzyloxycarbonyl)-amino]hexanoic acid methyl ester 1.5 g (5.1 mmol) and di-*tert*-butyl-dicarbonat (3.1 g, 14.0 mmol) with 10 % Pd/C (0.28 g) in methanol under 4 atm pressure of H<sub>2</sub> overnight. The solution was filtered

through Celite and evaporated. Purification by flash chromatography, yield 0.90 g (3.7 mmol).

#### **4-Phenylbutanoyl-5(R)-methyl-L-proline ethyl ester**

- 5    4-Phenylbutanoylchloride (prepared from 4-phenylbutanoic acid (0.73 g, 4.4 mmol) and thionyl chloride (0.64 ml, 8.9 mmol)) was added to a solution of the 5(R)-methyl-L-proline ethyl ester trifluoroacetic acid salt (prepared from Boc-5(R)-methyl-L-proline ethyl ester (0.90 g, 3.7 mmol) according to procedure E) and triethyl amine (2.1 ml, 15.0 mmol) in dichloromethane at 0 °C, where after it was stirred at rt for 3 h. The  
 10    dichloromethane phase was washed with 30 % citric acid, saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 0.74 g (2.6 mmol).

#### **4-Phenylbutanoyl-5(R)-methyl-L-proline**

- 15    The ethyl ester group of 4-phenylbutanoyl-5(R)-methyl-L-proline ethyl ester (0.74 g, 2.6 mmol) was hydrolyzed according to procedure D. Yield 0.67 g (2.4 mmol).

#### **4-Phenylbutanoyl-5(R)-methyl-L-prolyl-pyrrolidine**

- 4-Phenylbutanoyl-5(R)-methyl-L-proline (0.67 g, 2.4 mmol) and pyrrolidine (0.22 ml, 2.7 mmol) were coupled according to procedure C. Purification by flash chromatography, yield 0.53 g (1.6 mmol).

<sup>13</sup>C NMR: δ 20.51, 24.16, 26.21, 26.22, 26.99, 32.85, 32.89, 35.21, 46.02, 46.35, 54.28, 58.87, 125.80, 128.27, 128.52, 141.75, 170.69, 171.03.

- Anal. (C<sub>20</sub>H<sub>28</sub>N<sub>2</sub>O<sub>2</sub> · 0.3 H<sub>2</sub>O) calcd C: 71.95, H: 8.63, N: 8.39; found C: 72.14, H: 8.76,  
 25    N: 8.34.

### **EXAMPLE 8**

#### **4-Phenylbutanoyl-5(R)-methyl-L-prolyl-2(S)-(acetoxyacetyl)-pyrrolidine**

- 30    4-Phenylbutanoyl-5(R)-methyl-L-proline (0.23 g, 0.84 mmol) and 2(S)-(acetoxyacetyl)-pyrrolidine trifluoroacetic acid salt (prepared from Boc-2(S)-(acetoxyacetyl)-pyrrolidine (0.23 g, 0.84 mmol) according to procedure E) were coupled according to procedure C. Purification by flash chromatography, yield 0.23 g (0.54 mmol).

**4-Phenylbutanoyl -5(*R*)-methyl-L-prolyl-2(*S*)-(hydroxyacetyl)-pyrrolidine**

Prepared according to procedure F using 4-phenylbutanoyl-5(*R*)-methyl-L-prolyl-2(*S*)-(acetoxyacetyl)-pyrrolidine (0.23 g, 0.54 mmol) as starting material. Purification by flash

5 chromatography, yield 0.11 g (0.29 mmol).

$^{13}\text{C}$  NMR:  $\delta$  20.65, 25.34, 26.23, 26.82, 28.25, 32.84, 32.90, 35.23, 47.19, 54.30, 58.56, 61.27, 66.96, 125.88, 128.32, 128.50, 141.66, 171.21, 171.33, 209.05.

ESI-MS:  $m/z$  387 ( $\text{M}+\text{H}$ ) $^+$ .

Anal. ( $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_4 \cdot 0.5 \text{ H}_2\text{O}$ ) calcd C: 66.81, H: 7.90, N: 7.08; found C: 66.82, H: 7.83,

10 N: 6.83.

**EXAMPLE 9****Boc-5(*R*)-*tert*-butyl-L-proline methyl ester**

15 Prepared according to Lubell, W. D. *et al.* (*J. Org. Chem.* 1996, 61, 9447-9454), with the small modification that the 9-(9-phenylfluorenyl) protecting group was replaced by the trityl protecting group in the synthesis procedure. The major diastereomer was isolated by flash chromatography.

**Boc-5(*R*)-*tert*-butyl-L-proline**

The methyl ester group of Boc-5(*R*)-*tert*-butyl-L-proline methyl ester (1.14 g, 4.0 mmol) was hydrolyzed according to procedure D. Yield 0.88 g (3.2 mmol).

**Boc-5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine**

25 Boc-5(*R*)-*tert*-butyl-L-proline (0.88 g, 3.2 mmol) and pyrrolidine (0.27 ml, 3.2 mmol) were coupled according to procedure C. Purification by flash chromatography, yield 0.87 g (2.7 mmol).

$^{13}\text{C}$  NMR:  $\delta$  24.09, 26.35, 27.08, 27.59, 28.38, 28.85, 36.36, 45.96, 45.99, 61.00, 66.69, 79.60, 156.21, 171.15.

30 ESI-MS:  $m/z$  325 ( $\text{M}+\text{H}$ ) $^+$ .

Anal. ( $\text{C}_{18}\text{H}_{32}\text{N}_2\text{O}_3$ ) calcd C: 66.63, H: 9.94, N: 8.63; found C: 66.28, H: 9.95, N: 8.57.

**EXAMPLE 10****Acetyl-5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine**

Acetic anhydride (0.15 ml, 1.5 mmol) was added to a solution of the 5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine trifluoroacetic acid salt (prepared from Boc-5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine (0.25 g, 0.77 mmol) according to procedure E) and triethyl amine (0.40 ml, 3.1 mmol) in dichloromethane at 0 °C. The reaction was stirred at rt for 3 h. The dichloromethane solution was washed with 30 % citric acid, saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 0.17 g (0.65 mmol).

<sup>13</sup>C NMR: δ 22.74, 23.17, 23.94, 24.08, 26.25, 26.29, 26.42, 27.61, 27.95, 28.12, 29.65, 36.62, 36.64, 45.97, 45.98, 46.01, 46.31, 60.78, 61.81, 65.64, 68.18, 170.30, 170.46, 172.00, 172.02 (all except one carbon give double peaks).  
ESI-MS: *m/z* 267 (M+H)<sup>+</sup>.

Anal. (C<sub>15</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>) calcd C: 67.63, H: 9.84, N: 10.52; found C: 67.79, H: 10.16, N: 10.68.

**EXAMPLE 11****4-Phenylbutanoyl-5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine**

4-Phenylbutanoylchloride (prepared from 4-phenylbutanoic acid (0.39 g, 2.4 mmol) and thionyl chloride (0.21 ml, 2.9 mmol)) was added to a solution of the 5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine trifluoroacetic acid salt (prepared from Boc-5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine (0.63 g, 1.9 mmol) according to procedure E) and triethyl amine (0.89 ml, 6.4 mmol) in dichloromethane at 0 °C. The reaction mixture was stirred at rt for 3 h. The dichloromethane phase was washed with 30 % citric acid, saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 0.61 g (1.6 mmol).

<sup>13</sup>C NMR: δ 23.90, 24.09, 25.92, 26.18, 26.34, 26.78, 27.41, 27.68, 27.93, 28.12, 29.60, 29.71, 33.07, 33.88, 35.12, 35.27, 36.44, 36.62, 45.76, 45.97, 46.00, 46.17, 60.82, 60.99, 65.72, 67.04, 125.74, 125.86, 128.25, 128.30, 128.51, 128.62, 141.75, 142.03, 170.34, 170.53, 173.99, 174.26.  
ESI-MS: *m/z* 371 (M+H)<sup>+</sup>.

Anal. ( $C_{23}H_{34}N_2O_2 \cdot 0.2 H_2O$ ) calcd C: 73.84, H: 9.27, N: 7.49; found C: 73.91, H: 9.35, N: 7.17.

### EXAMPLE 12

5

#### **4-Phenylbutanoyl-5(R)-*tert*-butyl-L-proline methyl ester**

4-Phenylbutanoylchloride (prepared from 4-phenylbutanoic acid (0.76 g, 4.6 mmol) and thionyl chloride (0.50 ml, 6.9 mmol)) was added to a solution of the 5(R)-*tert*-butyl-L-proline methyl ester trifluoroacetic acid salt (prepared from Boc-5(R)-*tert*-butyl-L-proline methyl ester (1.1 g, 3.8 mmol) according to procedure E) and triethyl amine (2.1 ml, 15.3 mmol) in dichloromethane at 0 °C. The reaction was stirred 4 h in rt. The dichloromethane solution was washed with 30 % citric acid, saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 0.73 g (2.2 mmol).

15

#### **4-Phenylbutanoyl-5(R)-*tert*-butyl-L-proline**

The methyl ester group of 4-phenylbutanoyl-5(R)-*tert*-butyl-L-proline methyl ester (0.68 g, 2.1 mmol) was hydrolyzed according to procedure D. Yield 0.58 g (1.8 mmol).

20

#### **4-Phenylbutanoyl-5(R)-*tert*-butyl-L-prolyl-2(S)-(acetoxymethyl)-pyrrolidine**

4-Phenylbutanoyl-5(R)-*tert*-butyl-L-proline (0.58 g, 1.8 mmol) and 2(S)-(acetoxymethyl)-pyrrolidine trifluoroacetic acid salt (prepared from Boc-2(S)-(acetoxymethyl)-pyrrolidine (0.50 g, 1.8 mmol) according to procedure E) were coupled according to procedure C. Purification by flash chromatography, yield 0.30 g (0.64 mmol).

25

#### **4-Phenylbutanoyl -5(R)-*tert*-butyl-L-prolyl-2(S)-(hydroxymethyl)-pyrrolidine**

Prepared according to procedure F using 4-phenylbutanoyl-5(R)-*tert*-butyl-L-prolyl-2(S)-(acetoxymethyl)-pyrrolidine (0.30 g, 0.64 mmol) as starting material. Purification by flash chromatography, yield 0.26 g (0.61 mmol).

30

<sup>13</sup>C NMR: δ 25.37, 25.42, 25.82, 26.06, 26.76, 27.15, 27.57, 27.82, 28.06, 28.07, 29.15, 29.43, 33.01, 33.79, 34.97, 35.24, 36.43, 36.53, 46.50, 46.79, 60.44, 60.63, 61.24, 61.30, 65.83, 66.90, 66.97, 67.08, 125.77, 125.91, 128.26, 128.33, 128.49, 128.65, 141.64, 141.97, 170.78, 171.01, 173.74, 174.39, 208.42, 209.31.

ESI-MS:  $m/z$  429 ( $M+H$ )<sup>+</sup>.

Anal. ( $C_{25}H_{36}N_2O_4 \cdot 0.1 H_2O$ ) calcd C: 69.77, H: 8.48, N: 6.51; found C: 69.62, H: 8.48, N: 6.73.

## 5 EXAMPLE 13

### **Benzylcarbamoyl-5(*R*)-*tert*-butyl-L-prolyl-pyrrolidine**

Benzylisocyanate (0.55 ml, 4.5 mmol) was added to a solution of the 5(*R*)-*tert*-butyl-L-proline methyl ester trifluoroacetic acid salt (prepared from Boc-5(*R*)-*tert*-butyl-L-proline methyl ester (1.46 g, 4.5 mmol) according to procedure E) and triethyl amine (1.9 ml, 13.5 mmol) in dimethylformamide at 0 °C. The reaction was stirred 3 h in rt. The dimethylformamide solution was poured into ice-water and the product was extracted with dichloromethane. The dichloromethane phase was washed with 30 % citric acid, saturated NaCl and saturated NaHCO<sub>3</sub>. The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 1.24 g (3.5 mmol).

<sup>13</sup>C NMR: δ 23.90, 26.34, 26.84, 27.54, 29.32, 36.46, 44.96, 46.16, 46.33, 62.56, 66.51, 127.07, 127.41, 128.54, 139.56, 160.29, 171.54.

Anal. ( $C_{21}H_{31}N_3O_2$ ) calcd C: 70.55, H: 8.74, N: 11.75; found C: 70.72, H: 8.85, N: 12.08.

## 20 EXAMPLE 14

### **Boc-5(*S*)-methyl-L-proline ethyl ester**

Prepared according to Collado, I. et al. (*J. Org. Chem.* 1995, 60, 5011-5015). Purification without separating the diastereomers by flash chromatography. This procedure yields the (2*S*,5*S*) diastereomer as the major product.

### **4-Phenylbutanoyl-5(*S*)-methyl-L-proline ethyl ester**

4-Phenylbutanoylchloride (prepared from 4-phenylbutanoic acid (1.42 g, 8.6 mmol) and thionyl chloride (0.93 ml, 13.0 mmol)) was added to a solution of the 5(*S*)-methyl-L-proline ethyl ester trifluoroacetic acid salt (prepared from Boc-5(*S*)-methyl-L-proline ethyl ester (1.85 g, 7.2 mmol) according to procedure E) and triethyl amine (4.0 ml, 28.7 mmol) in dichloromethane at 0 °C. The reaction was stirred 3 h in rt. The dichloromethane phase was washed with 30 % citric acid, saturated NaCl and saturated

$\text{NaHCO}_3$ . The dichloromethane phase was dried and evaporated. Purification by flash chromatography, yield 1.56 g (5.1 mmol).

**4-Phenylbutanoyl-5(S)-methyl-L-proline**

- 5 The ethyl ester group of 4-phenylbutanoyl-5(S)-methyl-L-proline ethyl ester (1.54 g, 5.1 mmol) was hydrolyzed according to procedure D. Yield 1.36 g (4.9 mmol).

**4-Phenylbutanoyl-5(S)-methyl-L-prolyl-pyrrolidine**

- 4-Phenylbutanoyl-5(S)-methyl-L-proline (0.67 g, 2.4 mmol) and pyrrolidine (0.20 ml, 2.4 mmol) were coupled according to procedure C. Purification by flash chromatography, yield 0.64 g (2.0 mmol).

$^{13}\text{C}$  NMR:  $\delta$  21.72, 24.15, 26.25, 26.51, 26.54, 31.72, 32.99, 35.11, 45.87, 46.22, 53.72, 58.06, 125.76, 128.26, 128.64, 141.95, 170.53, 171.70.

Anal. ( $\text{C}_{20}\text{H}_{28}\text{N}_2\text{O}_2 \cdot 0.2 \text{ H}_2\text{O}$ ) calcd C: 72.34, H: 8.62, N: 8.44; found C: 72.08, H: 8.86, N: 8.55.

**EXAMPLE 15**

**4-Phenylbutanoyl-5(S)-methyl-L-prolyl-2(S)-(acetoxyacetyl)-pyrrolidine**

- 20 Prepared according to procedure C using 4-phenylbutanoyl-5(S)-methyl-L-proline (0.69 g, 2.5 mmol) and 2(S)-(acetoxyacetyl)-pyrrolidine trifluoroacetic acid salt (prepared from Boc-2(S)-(acetoxyacetyl)-pyrrolidine (0.68 g, 2.5 mmol) according to procedure E). Purification by flash chromatography, yield 0.26 g (0.61 mmol).

25 **4-Phenylbutanoyl -5(S)-methyl-L-prolyl-2(S)-(hydroxyacetyl)-pyrrolidine**

Prepared according to procedure F using 4-phenylbutanoyl-5(S)-methyl-L-prolyl-2(S)-(acetoxyacetyl)-pyrrolidine (0.26 g, 0.61 mmol) as starting material. Purification by flash chromatography, yield 0.15 g (0.38 mmol).

$^{13}\text{C}$  NMR:  $\delta$  21.58, 25.34, 26.12, 26.44, 28.19, 31.60, 32.95, 35.14, 46.99, 53.81, 57.69, 60.94, 67.06, 125.83, 128.29, 128.55, 141.79, 171.01, 171.79, 209.19.

ESI-MS:  $m/z$  387 ( $\text{M}+\text{H}$ )<sup>+</sup>.

Anal. ( $\text{C}_{22}\text{H}_{30}\text{N}_2\text{O}_4 \cdot 0.4 \text{ H}_2\text{O}$ ) calcd C: 67.12, H: 7.89, N: 7.12; found C: 67.19, H: 7.88, N: 6.95.

**EXAMPLE 16****Boc-5(S)-*tert*-butyl-L-proline ethyl ester**

- 5 CuBr·Me<sub>2</sub>S (4.11 g, 20 mmol) in anhydrous tetrahydrofuran (40 ml) was cooled to -80 °C and 1.5 M *tert*-butyllithium (13.3 ml, 20 mmol) was added. After 30 min BF<sub>3</sub>·Et<sub>2</sub>O (2.5 ml, 20 mmol) was added and after further 20 min a solution of Boc-5-methoxy-L-proline ethyl ester (1.28 g, 4.7 mmol) (prepared according to Collado, I. *et al.* (*J. Org. Chem.* 1995, 60, 5011-5015)) in anhydrous tetrahydrofuran (10 ml) was added. The reaction mixture was stirred for 15 min at -80 °C, where after it was allowed to warm to room temperature during 3 h. A mixture of 25 % NH<sub>3</sub> (12 ml) and saturated NH<sub>4</sub>Cl (12 ml) was added and the reaction was stirred 1 h at room temperature. The tetrahydrofuran layer was separated and evaporated. The residue was dissolved in diethyl ether. The remaining aqueous layer was extracted with diethyl ether. Both diethyl ether layers were combined
- 10 and washed with saturated NaHCO<sub>3</sub>, dried and evaporated. Purification by flash chromatography without separation of diastereomers, yield 1.27 g (4.2 mmol). This
- 15 procedure yields the (2*S*,5*S*)-diastereomer as the major product.

**Boc-5(S)-*tert*-butyl-L-proline**

- 20 The ethyl ester group of Boc-5(S)-*tert*-butyl-L-proline ethyl ester (1.23 g, 4.1 mmol) was hydrolyzed according to procedure D with prolonged reaction time. Yield 0.62 g (2.3 mmol).

**Boc-5(S)-*tert*-butyl-L-prolyl-pyrrolidine**

- 25 Boc-5(S)-*tert*-butyl-L-proline (0.62 g, 2.3 mmol) and pyrrolidine (0.19 ml, 2.3 mmol) were coupled according to procedure C. Purification by flash chromatography, yield 0.43 g (1.3 mmol).

<sup>13</sup>C NMR: δ 24.19, 25.03, 26.33, 27.52, 28.24, 29.66, 36.89, 45.91, 46.06, 60.18, 66.25, 79.01, 155.79, 172.02.

- 30 ESI-MS: *m/z* 325 (M+H)<sup>+</sup>.

Anal. (C<sub>18</sub>H<sub>32</sub>N<sub>2</sub>O<sub>3</sub>) calcd C: 66.63, H: 9.94, N: 8.63; found C: 66.77, H: 10.30, N: 8.75.

**EXAMPLE 17****(±)-2-Formyl-cyclopent-2-enecarboxylic acid pyrrolidine amide**

2-Formyl-cyclopent-2-enecarboxylic acid (0.50 g, 3.6 mmol) and pyrrolidine (0.30 ml,

- 5      3.6 mmol) were coupled according to procedure C. Purification by flash chromatography,  
yield 0.50 g (2.6 mmol).

**2-(Hydroxy-pyridin-3-yl-methyl)-cyclopent-2-enecarboxylic acid pyrrolidine amide**

To a solution of 3-iodopyridine (0.29 g, 1.4 mmol) in 10 ml of anhydrous THF was added

- 10     1 M solution of ethylmagnesium bromide in THF (1.7 ml, 1.7 mmol) at rt. After 30 min,  
(±)-2-formyl-cyclopent-2-enecarboxylic acid pyrrolidine amide (0.25 g, 1.3 mmol) in  
anhydrous THF was added and the mixture was stirred for 4 h. The reaction mixture was  
poured into cold saturated NH<sub>4</sub>Cl and the solution was acidified with hydrochloric acid  
and washed with DCM. Purification by flash chromatography, yield 0.17 g (0.62 mmol).

15

**2-Nicotinoyl-cyclopent-2-enecarboxylic acid pyrrolidine amide**

2-(Hydroxy-pyridin-3-yl-methyl)-cyclopent-2-enecarboxylic acid pyrrolidine amide (0.17  
g, 0.62 mmol) was oxidized according to procedure B at -20 °C. The reaction mixture  
was washed with 5 % NaOH. Purification by flash chromatography, yield 55 mg (0.20  
mmol).

<sup>13</sup>C NMR: δ 24.42, 26.16, 27.77, 33.95, 45.86, 46.90, 49.41, 123.21, 133.96, 136.61,  
144.16, 148.14, 150.14, 152.56, 172.49, 191.93.

ESI-MS: *m/z* 271 (M+H)<sup>+</sup>.

Anal. (C<sub>16</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> · 0.6 H<sub>2</sub>O) calcd C: 68.36, H: 6.88, N: 9.96; found C: 68.70, H: 6.90,

25     N: 9.60.

**DETERMINATION OF INHIBITORY EFFECT OF NOVEL COMPOUNDS ON  
PROLYL OLIGOPEPTIDASE ACTIVITY OF PIG BRAIN**

- 30     The inhibitory effect of the novel compounds on POP activity of pig brain was  
determined with a method based on that described by Toide *et al.* (Toide, K, Iwamoto,  
Y., Fujiwara. T., Abe, H., *J.Pharmacol.Exp.Ther.*, 1995, 274, 1370-1378) for the rat  
enzyme.

The whole pig brains, excluding cerebellum and most of the brain stem, of three pigs were placed in liquid nitrogen within 30 min from killing and stored at -80°C until homogenized. The brains were homogenized with a glass-teflon homogenisator in 3 volumes (w/v) of ice-cold 0.1 M sodium-potassium phosphate buffer (pH 7.0) and the homogenates were centrifuged for 20 min at 4°C at 10000 g. The supernatants were collected, pooled and stored in small aliquots at -80°C until used. The supernatant was thawed in ice just before activity assay and diluted in a ratio 1:2 with homogenisation buffer (= enzyme preparation).

- 5      homogenates were centrifuged for 20 min at 4°C at 10000 g. The supernatants were  
collected, pooled and stored in small aliquots at -80°C until used. The supernatant was  
thawed in ice just before activity assay and diluted in a ratio 1:2 with homogenisation  
buffer (= enzyme preparation).
- 10     In the microplate assay procedure, 10 µl of enzyme preparation was preincubated with  
460 µl of 0.1 M sodium-potassium phosphate buffer (pH 7.0) and 5 µl of a solution of  
novel compound dissolved in DMSO and diluted with 0.1 M sodium-potassium  
phosphate buffer at 30°C for 30 min. The controls contained 10 µl enzyme preparation  
and 465 µl of 0.1 M sodium-potassium phosphate buffer (pH 7.0). The reaction was  
15    initiated by adding 25 µl of 4 mM Suc-Gly-Pro-AMC (AMC: 7-amido-4-  
methylcoumarin) dissolved in 0.1 M sodium-potassium phosphate buffer (pH 7.0), and  
the mixture was incubated at 30°C for 60 min. The reaction was terminated by adding  
500 µl of 1 M sodium acetate buffer (pH 4.2).
- 20     Formation of 7-amido-4-methylcoumarin was determined fluorometrically with  
microplate fluorescence reader (excitation at 360 nm and emission at 460 nm). The final  
concentration of novel compounds in the assay mixture varied from  $10^{-12}$  M to  $10^{-4}$  M.

- 25     The prolyl oligopeptidase activity was calculated with the following formula in the  
presence of various concentrations of novel compounds. To reveal the inhibitory potency  
of the novel compound, activities (% of control) were plotted against the log  
concentration of the compound, and the IC<sub>50</sub> value was determined by non-linear  
regression utilizing GraphPad Prism software.

- 30     Activity (% of control) = a/b × 100, where  
a = fluorescence intensity in the presence of a novel compound  
b = fluorescence intensity without a novel compound (control)

**Table 1: Inhibition of pig brain prolyl oligopeptidase.**

Compound of example No.	IC <sub>50</sub> [nM]
1	0.38
2	0.32
3	9
4	7.7
5	0.21
6	1.3
7	0.71
8	0.15
9	2.2
11	1.6
12	0.24
14	1.4
15	0.17
16	9.2

The novel compounds exhibit high inhibition potency against pig brain prolyl oligopeptidase. The results are summarized in Table 1.

5

#### **Inhibitory activity against other proline specific proteases**

The novel compounds were tested for specificity of inhibitory activity against formation of 7-amido-4-methylcoumarin from specific substrates of other proline specific

10 peptidases in the pig brain.

#### **Determination of inhibitory effect of novel compounds on dipeptidyl peptidase II activity of pig brain**

15 By following the procedure for determination of inhibitory effect of novel compounds on prolyl oligopeptidase, but initiating the reaction by adding 25 µl of 0.4 mM H-Lys-Ala-

AMC dissolved in 0.1 M sodium-potassium phosphate buffer (pH 7.0), and incubating the mixture at 30°C for 30 min, the formation of 7-amido-4-methylcoumarin was determined. The dipeptidyl peptidase II inhibition was calculated with the following formula in the presence of a novel compound ( $10^{-6}$  M).

5

Percent inhibition (%) =  $(1 - c/d) \times 100$ , where

c = fluorescence intensity in the presence of novel compound

d = fluorescence intensity without novel compound (control)

- 10 The novel compounds did not exhibit any inhibitory effect against pig brain dipeptidyl peptidase II.

**Determination of inhibitory effect of novel compounds on dipeptidyl peptidase IV activity of pig brain**

15

By following the procedure for determination of inhibitory effect of novel compounds on prolyl oligopeptidase, but initiating the reaction by adding 25  $\mu$ l of 2 mM H-Gly-Pro-AMC dissolved in 0.1 M sodium-potassium phosphate buffer (pH 7.0), the formation of 7-amido-4-methylcoumarin was determined. The dipeptidyl peptidase IV inhibition was calculated with the formula described above in the presence of a novel compound ( $10^{-6}$  M).

20

The novel compounds did not exhibit any inhibitory effect against pig brain dipeptidyl peptidase IV.

or R<sub>3</sub> is COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub> or COCH<sub>2</sub>OR<sup>6</sup>, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl is unsubstituted or substituted with 1

- 5 or 2 substituent(s) each independently being cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is lower acyl or halogen; or a pharmaceutically acceptable salt or ester thereof,

10

provided, that

- a) when X is N, the dotted line represents a single bond and R<sub>2</sub> is not H;
- b) when X is C, the dotted line represents a double bond and R<sub>2</sub> is H;
- c) the compound is not 5-ethoxycarbonyl-N-benzyloxycarbonyl-2-[(2'-(S)-benzylcarbonyl)-1'-pyrrolidinylcarbonyl]pyrrolidine or 1,2-pyrrolidinedicarboxylic acid, 5-(1-pyrrolidinylcarbonyl)-,1-(phenylmethyl) ester.

## 2. A compound according to claim 1, wherein

20 X is N;

the dotted line represents a single bond;

R<sub>1</sub> is:

- 25 a straight or branched alkyl chain having 1 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) each independently being COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub>, COCH<sub>2</sub>OR<sup>6</sup>, cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, nitro, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, 30 cycloalkyl or heterocycle, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl or aralkyl, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is H, lower alkyl, lower acyl or halogen,

a straight or branched alkenyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group above,

5 a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted

with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,

10 a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined

for the alkyl group above,

15 a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as defined above,

20 hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;

25 R<sub>2</sub> is:

a straight or branched alkyl chain having 1 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) each independently being hydroxy, oxo, lower alkoxy, amino, lower alkyl amino, halogen, carboxyl or lower acyl,

30 a straight or branched alkenyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>2</sub>, above,

or a straight or branched alkynyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>2</sub>, above;

$R_3$  is:

H, cyano, hydroxy, oxo, halogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl lower

5 alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein the said alkyl subgroups are unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of  $R_1$ , above,

or  $R_3$  is  $\text{COOR}^4$ ,  $\text{COR}^4$ ,  $\text{CR}^4(\text{OR}^5)_2$  or  $\text{COCH}_2\text{OR}^6$ , wherein  $R^4$  is H, lower alkyl, lower

10 alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,  $R^5$  is lower alkyl, lower alkenyl, cycloalkyl,

15 cycloalkenyl, aryl or aralkyl and  $R^6$  is lower acyl or halogen, or a pharmaceutically acceptable salt or ester thereof.

3. A compound according to claim 2, wherein

20  $R_1$  is

a straight or branched alkyl chain having 1 to 5 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,

25 a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,

a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined

30 for the alkyl group above,

a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as defined above,

hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;

5

$R_2$  is

a straight or branched alkyl chain having 1 to 5 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, oxo, lower alkoxy, amino, lower alkyl amino, halogen, carboxyl or lower acyl;

10

$R_3$  is:

H, cyano or  $COR^4$ , wherein  $R^4$  is H, lower alkyl, cycloalkyl, cycloalkenyl, heterocycle or aryl, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkyl, cycloalkyl or heterocycle.

15

4. A compound according to any one of claims 2 or 3, wherein

$R_1$  is

20 a straight alkyl chain having 1 to 3 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being aryl, aryloxy, aryl lower alkoxy, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, a 3 to 7 membered, saturated or unsaturated, unsubstituted heterocyclic ring, lower alkoxy, lower alkyl amino, aryl amino or aryl lower alkyl amino;

25

$R_2$  is a straight or branched unsubstituted alkyl chain having 1 to 4 carbon atoms;

$R_3$  is:

30 H, cyano or  $COR^4$ , wherein  $R^4$  is H or lower alkyl, wherein the said lower alkyl is unsubstituted or substituted with hydroxy.

5. A compound according to claim 1, wherein

X is C;

the dotted line represents a double bond;

5 R<sub>1</sub> is:

- a straight or branched alkyl chain having 1 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) each independently being COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub>, COCH<sub>2</sub>OR<sup>6</sup>, cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, nitro, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl or aralkyl, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is H, lower alkyl, lower acyl or halogen,
- 10 15 a straight or branched alkenyl chain having 2 to 10 carbon atoms unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group above,
- 20 a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,
- 25 a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,
- 30 hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;

R<sub>2</sub> is H;

R<sub>3</sub> is:

5

H, cyano, hydroxy, oxo, halogen, lower alkyl, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, wherein the said alkyl subgroups are unsubstituted or substituted with 1 to 3 substituent(s) as defined for the alkyl group, in the meaning of R<sub>1</sub>, above,

10

or R<sub>3</sub> is COOR<sup>4</sup>, COR<sup>4</sup>, CR<sup>4</sup>(OR<sup>5</sup>)<sub>2</sub> or COCH<sub>2</sub>OR<sup>6</sup>, wherein R<sup>4</sup> is H, lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, heterocycle, aryl, amino, lower alkyl amino, aryl amino or lower alkyl amino, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being cyano, hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle, R<sup>5</sup> is lower alkyl, lower alkenyl, cycloalkyl, cycloalkenyl, aryl or aralkyl and R<sup>6</sup> is lower acyl or halogen, or a pharmaceutically acceptable salt or ester thereof.

15 20 6. A compound according to claim 5, wherein

R<sub>1</sub> is

a straight or branched alkyl chain having 1 to 5 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, halogen, lower alkoxy, aryl, 25 aryloxy, aryl lower alkoxy, amino, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,  
a 3 to 7 membered, saturated or unsaturated, carbocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,  
30 a 3 to 7 membered, saturated or unsaturated, heterocyclic ring unsubstituted or substituted with 1 or 2 substituent(s) each independently being lower alkyl or as defined for the alkyl group above,  
a substituted or unsubstituted alkyl or alkenyl group as defined above incorporating as a

group member a substituted or unsubstituted carbocyclic ring or a heterocyclic ring as defined above,

hydroxy, lower alkoxy, aryloxy, aryl lower alkoxy, amino, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the said alkyl, aryl or amino

- 5 subgroups are unsubstituted or substituted with 1 to 3 substituent(s) each independently being lower alkyl or as defined for the alkyl group above;

R<sub>3</sub> is:

H, cyano or COR<sup>4</sup>, wherein R<sup>4</sup> is H, lower alkyl, cycloalkyl, cycloalkenyl, heterocycle or

- 10 aryl, wherein the said lower alkyl is unsubstituted or substituted with 1 or 2 substituent(s) each independently being hydroxy, oxo, halogen, lower alkoxy, aryl, aryloxy, aryl lower alkoxy, cycloalkyl or heterocycle.

7. A compound according to any one of claims 5 or 6, wherein

15

R<sub>1</sub> is

a straight or branched alkyl chain having 1 to 3 carbon atoms unsubstituted or substituted with 1 or 2 substituent(s) each independently being, aryl, aryloxy, aryl lower alkoxy, lower alkyl amino, aryl amino, aryl lower alkyl amino, cycloalkyl or heterocycle,

- 20 a 3 to 7 membered, saturated or unsaturated, unsubstituted heterocyclic ring, lower alkoxy, amino lower alkyl, lower alkyl amino, aryl amino or aryl lower alkyl amino, wherein the amino subgroups are unsubstituted or substituted with lower alkyl;

R<sub>3</sub> is:

- 25 H, cyano or COR<sup>4</sup>, wherein R<sup>4</sup> is H or lower alkyl, wherein the said lower alkyl is unsubstituted or substituted with hydroxy.

8. A pharmaceutical composition comprising at least one compound of formula (I) according to any one of claims 1 to 7 and a pharmaceutically acceptable diluent, carrier  
30 and/or excipient.

9. A compound of formula (I) according to any one of claims 1 to 7 for use as a prolyl oligopeptidase inhibitor.

10. The use of a compound of formula (I) or a pharmaceutically acceptable ester or salt thereof according to any one of claims 1 to 7 for the manufacture of a medicament for use as a prolyl oligopeptidase inhibitor.

5

11. The use of a compound of formula (I) according to any one of claims 1 to 7 for the manufacture of a medicament for the treatment of neurodegenerative diseases, and/or for the improvement of learning and memory functions.

10 12. The use according to claim 11, wherein the neurodegenerative disease is Alzheimer's disease or senile dementia.

13. A method for the treatment of a disease or the enhancement of a condition where prolyl oligopeptidase inhibitors are indicated to be useful, which comprises administering 15 to a subject in need of the treatment an effective amount of at least one compound of formula (I) according to claim 1.

14. The method according to claim 13, which comprises treating a neurodegenerative disease, and/or improving learning and memory functions.

20

15. The method according to claim 14, wherein the neurodegenerative disease is Alzheimer's disease or senile dementia.